menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Adopting the New Therapeutic “Lineup” to Manage ASCVD - West

Join expert faculty to ensure you’re appropriately managing the care of your patients with ASCVD.

Live Meeting
3.50 available credits
Information
March 19, 2022
07:45 AM - 12:00 PM PDT
San Jose Marriott
301 S. Market Street, - San Jose Ballroom: Salon III & IV -, San Jose, California, United States
San Jose Marriott
ReachMD Healthcare Image
Choose a format
Details
Presenters
Comments
  • Overview

    Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided. 

  • Program Schedule*

    7:45 am–8:30 am

    Registration and Breakfast

    8:30 am–8:35 am

    Welcome, Introductions, Program Overview
    Karol Watson, MD
    Program Chair

    8:35 am–8:45 am

    Burden of Heart Disease Today
    Charles Vega, MD

    8:45 am–9:15 am

    Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
    Pam Taub, MD

    9:15 am–9:45 am

    REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
    Karol Watson, MD

    9:45 am–10:00 am

    Panel Discussion
    All faculty

    10:00 am–10:15 am

    Break

    10:15 am–10:30 am

    Recent Evidence from REDUCE-IT Sub-studies
    Karol Watson, MD

    10:30 am–11:00 am

    Differential Biological Effects of Omega-3 Fatty Acids
    Pam Taub, MD

    11:00 am–11:20 am

    Role of Pharmacist in Establishing Lipid Intervention
    Joseph Saseen, PharmD, BCPS, BCACP

    11:20 am–11:35 am

    Panel Discussion
    All Faculty

     11:35 am–11:55 am

    Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
    All Faculty

    11:55 am–12:00 pm   

    Closing Comments, Adjourn
    Karol Watson, MD

    *Subject to change

  • Disclosure of Conflicts of Interest

    Chair:

    Karol Watson, MD, PhD
    Professor of Medicine/Cardiology
    Co-director, UCLA Program in Preventive Cardiology
    Director, UCLA Barbra Streisand Women's Heart Health Program
    David Geffen School of Medicine at UCLA
    Los Angeles, CA
    Consulting Fees: Amarin, Amgen, Boehringer-Ingelheim, Lilly, Esperion, Novo Nordisk

    Faculty:

    Joseph Saseen, PharmD, BCPS, BCACP, CLS
    Professor, Departments of Clinical Pharmacy and Family Medicine
    Vice Chair, Department of Clinical Pharmacy
    Skaggs School of Pharmacy and Pharmaceutical Sciences
    University of Colorado Anschutz Medical Campus
    Aurora, CONo relationship reported
    No relationship reported

    Pam R. Taub, MD, FACC, FASPC
    Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
    Professor of Medicine
    UC San Diego Health System
    Division of Cardiovascular Medicine
    La Jolla, CA 
    Consultant/Advisory Board:   Amarin, Amgen, Bayer, Boehringer-Ingelheim, Esperion,
    Medtronic, Novartis, Novo-Nordisk, Sanofi
    Ownership Interest: Founder and Shareholder of Epirium Bio

    Charles P. Vega, MD
    Health Sciences Clinical Professor, UC Irvine Department of Family Medicine
    Assistant Dean, Culture and Community Education, UC Irvine School of Medicine
    Executive Director, UC Irvine Program in Medical Education for the Latino Community
    UC Irvine School of Medicine
    Orange, CA
    No relationship reported

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose. 
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, MS has nothing to disclose.
    • Kathy Wickman has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
    • Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
    • Identify barriers to the implementation of effective, long-term management of ASCVD
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians and community pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.

Facebook Comments

Details
Presenters
Comments
Recommended
  • Overview

    Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided. 

  • Program Schedule*

    7:45 am–8:30 am

    Registration and Breakfast

    8:30 am–8:35 am

    Welcome, Introductions, Program Overview
    Karol Watson, MD
    Program Chair

    8:35 am–8:45 am

    Burden of Heart Disease Today
    Charles Vega, MD

    8:45 am–9:15 am

    Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
    Pam Taub, MD

    9:15 am–9:45 am

    REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
    Karol Watson, MD

    9:45 am–10:00 am

    Panel Discussion
    All faculty

    10:00 am–10:15 am

    Break

    10:15 am–10:30 am

    Recent Evidence from REDUCE-IT Sub-studies
    Karol Watson, MD

    10:30 am–11:00 am

    Differential Biological Effects of Omega-3 Fatty Acids
    Pam Taub, MD

    11:00 am–11:20 am

    Role of Pharmacist in Establishing Lipid Intervention
    Joseph Saseen, PharmD, BCPS, BCACP

    11:20 am–11:35 am

    Panel Discussion
    All Faculty

     11:35 am–11:55 am

    Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
    All Faculty

    11:55 am–12:00 pm   

    Closing Comments, Adjourn
    Karol Watson, MD

    *Subject to change

  • Disclosure of Conflicts of Interest

    Chair:

    Karol Watson, MD, PhD
    Professor of Medicine/Cardiology
    Co-director, UCLA Program in Preventive Cardiology
    Director, UCLA Barbra Streisand Women's Heart Health Program
    David Geffen School of Medicine at UCLA
    Los Angeles, CA
    Consulting Fees: Amarin, Amgen, Boehringer-Ingelheim, Lilly, Esperion, Novo Nordisk

    Faculty:

    Joseph Saseen, PharmD, BCPS, BCACP, CLS
    Professor, Departments of Clinical Pharmacy and Family Medicine
    Vice Chair, Department of Clinical Pharmacy
    Skaggs School of Pharmacy and Pharmaceutical Sciences
    University of Colorado Anschutz Medical Campus
    Aurora, CONo relationship reported
    No relationship reported

    Pam R. Taub, MD, FACC, FASPC
    Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
    Professor of Medicine
    UC San Diego Health System
    Division of Cardiovascular Medicine
    La Jolla, CA 
    Consultant/Advisory Board:   Amarin, Amgen, Bayer, Boehringer-Ingelheim, Esperion,
    Medtronic, Novartis, Novo-Nordisk, Sanofi
    Ownership Interest: Founder and Shareholder of Epirium Bio

    Charles P. Vega, MD
    Health Sciences Clinical Professor, UC Irvine Department of Family Medicine
    Assistant Dean, Culture and Community Education, UC Irvine School of Medicine
    Executive Director, UC Irvine Program in Medical Education for the Latino Community
    UC Irvine School of Medicine
    Orange, CA
    No relationship reported

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose. 
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, MS has nothing to disclose.
    • Kathy Wickman has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
    • Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
    • Identify barriers to the implementation of effective, long-term management of ASCVD
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians and community pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.

Facebook Comments

Schedule18 Jan 2022
Webpack App